Athira Pharma (NASDAQ:ATHA) Now Covered by BTIG Research

Investment analysts at BTIG Research began coverage on shares of Athira Pharma (NASDAQ:ATHAGet Rating) in a research note issued on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $33.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 273.30% from the company’s previous close.

Several other analysts have also recently commented on ATHA. Zacks Investment Research cut shares of Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. JMP Securities reiterated a “buy” rating and issued a $51.00 target price on shares of Athira Pharma in a research note on Friday, March 25th. Finally, Berenberg Bank initiated coverage on shares of Athira Pharma in a research note on Thursday, April 21st. They issued a “buy” rating and a $33.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Athira Pharma currently has a consensus rating of “Buy” and an average target price of $29.40.

Shares of NASDAQ ATHA opened at $8.84 on Tuesday. Athira Pharma has a 12 month low of $8.51 and a 12 month high of $23.64. The company has a 50 day simple moving average of $11.06 and a two-hundred day simple moving average of $11.81. The stock has a market cap of $332.60 million, a price-to-earnings ratio of -6.23 and a beta of 3.25.

Athira Pharma (NASDAQ:ATHAGet Rating) last announced its quarterly earnings data on Thursday, March 24th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.24. During the same quarter last year, the firm earned ($0.24) EPS. Sell-side analysts forecast that Athira Pharma will post -2.66 earnings per share for the current fiscal year.

In other news, Director Kelly A. Romano bought 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 31st. The stock was purchased at an average cost of $13.11 per share, for a total transaction of $104,880.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 14.90% of the company’s stock.

A number of large investors have recently bought and sold shares of ATHA. Morgan Stanley raised its position in Athira Pharma by 30.4% during the first quarter. Morgan Stanley now owns 22,445 shares of the company’s stock worth $413,000 after acquiring an additional 5,230 shares during the period. Bank of America Corp DE raised its position in Athira Pharma by 56.3% during the second quarter. Bank of America Corp DE now owns 16,749 shares of the company’s stock worth $172,000 after acquiring an additional 6,036 shares during the period. SG Americas Securities LLC acquired a new position in Athira Pharma during the third quarter worth $182,000. Deutsche Bank AG raised its position in Athira Pharma by 67.1% during the third quarter. Deutsche Bank AG now owns 38,480 shares of the company’s stock worth $361,000 after acquiring an additional 15,449 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in Athira Pharma during the third quarter worth $1,265,000. Institutional investors own 69.76% of the company’s stock.

About Athira Pharma (Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.

Featured Articles

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.